Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR2 | Q969V1 | 2/20 | 0.37 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2803155 | 0.92 | MCHR2 (0.38) | MCHR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL2800436 | 0.92 | NPC1L1 (0.39) | MCHR2NPC1L1PDE4BFFAR1HSD11B1 | |
| SCHEMBL2800570 | 0.90 | NPC1L1 (0.39) | MCHR2NPC1L1PDE4BFFAR1HSD11B1 | |
| SCHEMBL2801434 | 0.90 | MCHR2 (0.38) | MCHR2ALDH1A1MAPK1 | |
| SCHEMBL2800835 | 0.89 | MCHR2 (0.34) | MCHR2NPC1L1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2800771 | 0.85 | SMN1; SMN2 (0.36) | PDE4BSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL2799803 | 0.84 | PDE4B (0.38) | PDE4BSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL2801665 | 0.84 | RBP4 (0.46) | PDE4BSMN1; SMN2HSD11B1ALDH1A1MAPK1 | |
| SCHEMBL2800424 | 0.84 | ALDH1A1 (0.36) | PDE4BSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL2801037 | 0.83 | MCHR2 (0.38) | MCHR2NPC1L1PDE4BFFAR1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206714-B1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8729264-B2 | Agent for prevention and/or treatment of skin diseases | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-05-20 | — | — | US | disclosed |
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2206714-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | TYR, CUTA, SERPINB1 | MCHR2 4007/4885NPC1L1 3377/4885PDE4B 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.